CADTH publishes initial pCODR recommendation for entrectinib

CADTH

9 January 2021 - pERC has conditionally recommended the reimbursement of entrectinib for the first-line treatment of patients with ROS1 positive locally advanced or metastatic non-small cell lung cancer if certain conditions are met.

One of the conditions is that the cost effectiveness needs to be improved to an acceptable level.

Read pERC initial recommendation for entrectinib

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , Canada